(Q34494115)

2 August 2017

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer (English)

1 reference

2 August 2017

0 references

1 reference

Chee-Seng Tan

1

1 reference

PubMed ID

26370354

2 August 2017

David Gilligan

series ordinal

2

1 reference

PubMed ID

26370354

2 August 2017

Simon Pacey

series ordinal

3

1 reference

2 August 2017

1 September 2015

1 reference

Lancet Oncology Commission

2 August 2017

1 reference

2 August 2017

16

1 reference

2 August 2017

9

1 reference

2 August 2017

e447-59

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

EGFR mutations in small-cell lung cancers in patients who have never smoked.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

The quest to overcome resistance to EGFR-targeted therapies in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Development of therapeutic combinations targeting major cancer signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Adaptive designs for dual-agent phase I dose-escalation studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900246-6

7 January 2021

10.1016/S1470-2045(15)00246-6

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

26370354